<DOC>
	<DOCNO>NCT02751528</DOCNO>
	<brief_summary>The purpose study determine whether ETBX-021 safe effective treatment unresectable locally advanced metastatic HER2-low-expressing breast cancer .</brief_summary>
	<brief_title>QUILT-3.013 : Study Ad5 E1- , E2b -- HER2/Neu Vaccine ( ETBX-021 ) Subjects With Unresectable Locally Advanced Metastatic HER2-Expressing Breast Cancer</brief_title>
	<detailed_description>This Phase I trial subject unresectable locally advanced metastatic HER2-low expressing ( IHC 1+ 2+ ) breast cancer . The study conduct two part : first part involve dose escalation use 3 + 3 design , second part involve expansion MTD HTD evaluate safety , preliminary efficacy , immunogenicity . In first part , 3 6 subject sequentially enrol start dose cohort 1 . Subjects assess dose-limiting toxicity ( DLTs ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . Male female . 3 . Ability understand provide sign informed consent fulfills Institutional Review Board ( IRB ) 's guideline . 4 . Histologically confirm unresectable locally advanced metastatic breast cancer express HER2 ( IHC 1+ 2+ ) , derive recent metastatic biopsy sample available . 5 . Tumor tissue ( block slide ) whole blood sample available analysis . Archival tissue permit . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 7 . Concurrent hormone therapy permit . 8 . Subjects receive prior HER2targeted immunotherapy ( vaccine ) eligible trial treatment discontinue least 3 month prior enrollment . 9 . Resolution toxic side effect prior chemotherapy , radiotherapy , surgical procedure NCI CTCAE Grade ≤ 1 . 10 . Subjects take medication know history immunosuppression eligible trial . 11 . Adequate hematologic function screening , follow : White blood count ≥ 3000/microliter . Hemoglobin ≥ 9 g/dL ( may transfuse use erythropoietin achieve level ) . Platelets ≥ 75,000/microliter . Prothrombin ( PT ) international normalize ratio ( INR ) &lt; 1.5 . Partial thromboplastin time ( PTT ) &lt; 1.5 x upper limit normal ( ULN ) . 12 . Adequate renal hepatic function screening , follow : Serum creatinine &lt; 2.0 mg/dL . Bilirubin &lt; 1.5 mg/dL ( except Gilbert 's syndrome allow bilirubin ≤ 2.0 mg/dL ) . Alanine aminotransferase ( ALT ) ≤ 2.5 x ULN . Aspartate aminotransferase ( AST ) ≤ 2.5 x ULN . 13 . Multigated acquisition ( MUGA ) scan echocardiogram LVEF ≥ institutional LLN . Same image modality use throughout study . 14 . Female subject childbearing potential woman &lt; 12 month since onset menopause must agree use acceptable contraceptive method duration study 7 month follow last injection study medication . If employing contraception , two follow precaution must use : vasectomy partner , tubal ligation , vaginal diaphragm , intrauterine device , condom spermicidal ( gel/foam/cream/vaginal suppository ) , total abstinence . Male subject must surgically sterile must agree use condom acceptable contraceptive method partner . Female subject postmenopausal define absence menses &gt; 12 consecutive month . 15 . Ability attend require study visit return adequate follow , require protocol . 1 . Subjects HER2 IHC 3+ tumor , IHC 2+ situ hybridization ( ISH ) test result consider positive HER2 amplification ASCOCAP HER2 test guideline . 2 . Subjects ongoing HER2directed therapy , include trastuzumab , pertuzumab , TDM1 , lapatinib . 3 . Participation investigational drug device study within 30 day screen study . 4 . Pregnant nursing woman . 5 . Subjects ongoing palbociclib , everolimus , breast cancer therapy interfere induction immune response . 6 . Subjects concurrent cytotoxic chemotherapy radiation therapy . There must least 1 month prior chemotherapy ( radiotherapy ) study treatment . Any prior HER2targeted immunotherapy ( vaccine ) must discontinue least 3 month initiation study treatment . Subjects must recover acute toxicity prior treatment prior screen study . 7 . Active brain central nervous system metastasis , seizures require anticonvulsant treatment , cerebrovascular accident ( &lt; 6 month ) , transient ischemic attack . 8 . Subjects history autoimmune disease ( active past ) , restrict inflammatory bowel disease , systemic lupus erythematosus , ankylose spondylitis , scleroderma , multiple sclerosis . Autoimmunerelated thyroid disease vitiligo permit . 9 . Subjects serious intercurrent chronic acute illness , cardiac pulmonary disease , hepatic disease , illness consider Investigator high risk investigational drug treatment . 10 . Subjects history heart disease , congestive heart failure ( class II , III , IV define New York Heart Association functional classification ) , history unstable poorly control angina , history ( &lt; 1 year ) ventricular arrhythmia . 11 . Subjects medical psychological impediment would impair ability subject receive therapy per protocol impact ability comply protocol protocolrequired visit procedure . 12 . History malignancy except follow : adequately treat nonmelanoma skin cancer , cervical carcinoma situ , superficial bladder cancer , carcinoma complete remission without treatment 5 year . 13 . Presence know active acute chronic infection , include human immunodeficiency virus ( HIV , determine enzymelinked immunosorbent assay [ ELISA ] confirm western blot ) hepatitis B hepatitis C virus ( HBV/HCV , determine HBsAg hepatitis C serology ) . 14 . Subjects systemic intravenous oral steroid therapy ( immunosuppressive , azathioprine cyclosporin A ) exclude basis potential immune suppression . Subjects must least 6 week discontinuation steroid therapy ( except use premedication chemotherapy contrastenhanced study ) prior enrollment . 15 . Subjects know allergy hypersensitivity component investigational product exclude . 16 . Subjects acute chronic skin disorder interfere injection skin extremity subsequent assessment potential skin reaction exclude . 17 . Subjects vaccinate live ( attenuate ) vaccine ( e.g. , FluMist® ) kill ( inactivate ) /subunit vaccine ( e.g. , PNEUMOVAX® , Fluzone® ) within 28 day 14 day , respectively , first plan dose ETBX021 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Breast Cancer male</keyword>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Breast Neoplasms male</keyword>
	<keyword>Vaccine</keyword>
	<keyword>HER2</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Locally Advanced</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Cancer Vaccine</keyword>
</DOC>